Bristol-Myers Squibb Co at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Great. Good morning, everybody, and thanks for joining us for the fourth day of our conference. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. And I'm very pleased to have Bristol with us for the next session.
Before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.
So I'm going to turn it over to Giovanni to make some opening comments, and then we'll get right into it.
Thank you, Matthew, and good morning, everyone. It's a great opportunity to be able to spend some time with all of you. Let me just say for Bristol-Myers Squibb, we are getting close actually to 2 years after the acquisition of Celgene, and it's a really good time to reflect on where we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
